Claro Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Claro Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,637	Closed	-$221K	–	284
2022 Q1	$221K	Hold	3,637	–	–	0.08%	246
2021 Q4	$221K	Buy	+3,637	New	+$201K	0.08%	246

Other funds holding BCYC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Claro Advisors's BCYC Position: Q2 2022 in Review

Claro Advisors sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 3,637 shares — an estimated $221K sold.

Claro Advisors first reported a position in BCYC in Q4 2021 and held it in 2 quarters. The position peaked at $221K in Q1 2022. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

Claro Advisors reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
Claro Advisors sold 3,637 Bicycle Therapeutics shares in Q2 2022, an estimated $221K.
Claro Advisors first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 2 quarters.
Claro Advisors's Bicycle Therapeutics position peaked at $221K in Q1 2022.
81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on Claro Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.